I am not in the camp that thinks there will be a stop for efficacy. If the data were good and they were waiting for more data to stop for efficacy, they would have at minimum announced a continue while waiting for further data points. Generally a stop for futility comes at the second dmc, not the first, and this now long delay is becoming a concern. I am long NWBO but am starting to wonder #$%$ is going on, something is an issue, and no one is saying a word.
We can point to Germany, but if phase 3 fails, that gets yanked. Linda where R U, where is the dmc ?
We can point to the earlier studies too, but they are meaningless, the only study that matters is the current phase 3. Our coo Maida, was the ceo of cancervax. The phase 2 studies there were even better than the early studies here. I leave hunting that data to you, as part of dd. That said, the lead cancervax product failed phase 3, and strangely got stopped right after their asco presentation. Just found this out, and find the similar patterns concerning.
DD, does not mean to turn a blind eye, but look under every rock. The similarities between cancervax and nwbo strategies, and the fact the ceo of cancervax is on our board as coo is curious.
Will stay long, but getting concerned at this point.